Headlines

Novartis (NOVN SW) reported final 2.5-year Phase III ALIGN results showing slower kidney function decline with Vanrafia versus placebo in adults with IgA nephropathy

Newsquawk Staff ·

Novartis (NOVN SW) reported final 2.5-year Phase III ALIGN results showing slower kidney function decline with Vanrafia versus placebo in adults with IgA nephropathy.

Related headlines